- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04658914
Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in Africa
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, open-label clinical trial of Rotarix and trivalent VP8 subunit vaccine given alone or in combined schedules to 720 infants in Zambia at 6, 10 and 14 weeks followed by challenge at 18 weeks used to assess mucosal immunity.
Potential participants will be identified through antenatal and child health monitoring clinics in selected facilities in Lusaka Zambia. Interested parents will be invited to the clinical research site for informed consent procedures and assessment of eligibility. Children meeting the eligibility criteria with written informed consent for participation will be randomized to one of the four available study arms using simple randomization in block sizes of 8. Blood, stool, and saliva samples will be collected prior to completing vaccination according to randomization arm. All parents/guardians will be provided with post immunisation diary cards to document any reactions following vaccination. Trained study staff will contact parents and guardians of enrolled participants weekly to enquire on the child's health and assist with documentation of solicited reactions following vaccinations.
Enrolled children will be followed up for at least five months following enrollment. Follow up vaccinations will be provided each month until all children have completed all assigned study vaccinations. Upon completion of study vaccination, participants will be challenged with oral rotavirus vaccine, Rotarix TM to assess mucosal immunity.
Primary outcome:
The primary objective of the study will be to detect a reduction in the proportion of children shedding vaccine rotavirus in stool at any timepoint 5-9 days after challenge, among children immunized with P2-VP8 subunit vaccine alone or in combination with Rotarix, compared with infants receiving Rotarix alone. The primary outcomes will be prevalence of rotavirus (Rotarix) shedding at any timepoint in samples collected 5,7 and 9 days after challenge.
Secondary outcomes:
i.) Seroconversion following vaccination: Detection of an increase in seroconversion in either of the combined vaccination arms compared with Rotarix alone.
ii.) Immune boosting. We will compare the number of gut-homing (alpha 4 beta 7+) Immunoglobulin A (IgA) and Immunoglobulin G (IgG) rotavirus VP8-specific Antibody secreting cells (ASCs) 7 days after the third clinic visit in 50 infants from each study arm (i.e. after the first VP8 vaccine booster dose, after the third VP8 vaccine dose (alone or in combination with Rotarix), or after no vaccine (control) in the Rotarix only arm).
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Lusaka, Zambia, 10101
- Chawama first level hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy infants as established by medical history and physical examination.
- Infants will be 6-10 weeks old at time of enrollment
- parents plan to remain in the area for the duration of the study.
- Parent/guardian understands the study procedures and willing to provide informed consent to participate in the study
Exclusion Criteria:
- Acutely unwell
- Infant or infant's mother has syndromic or documented evidence of being immunocompromised (independent of HIV status)
- Known allergy to any vaccine component
- Previously received rotavirus vaccine
- Received immunosuppressive medication
- Major congenital or genetic abnormality
- Any condition in the parents/infant that, in the judgment of the investigator, would interfere with or serves as a contraindication to protocol adherence or a participant's parents' ability to give informed consent.
- Participant's parents not available or willing to accept active follow-up by the study staff
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
No Intervention: rotarix only
Rotarix will be administered at 6 and 10 weeks of age following the national Expanded Program for Immunization (EPI) schedule.
A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
|
|
Experimental: P2 VP8 only
Parenteral P2-VP8 subunit vaccine will be administered at 6, 10 and 14 weeks of age.
A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
|
Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P[4] (DS-1), P[6] (1076), and P[8] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide.
A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
|
Experimental: Rotarix + 1 dose P2-VP8
Rotarix will be administered at 6 and 10 weeks of age, followed by parenteral P2-VP8 subunit vaccine at 14 weeks of age.
A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
|
Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P[4] (DS-1), P[6] (1076), and P[8] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide.
A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10^6 CCID50(median cell culture infective doses) of G1P[8] rotavirus, RIX4414 strain produced in Vero cells.
This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
|
Experimental: Rotarix + 3 doses P2-VP8
Rotarix and parenteral P2-VP8 subunit vaccine will be coadministered at 6 and 10 weeks of age, with an additional dose of P2-VP8 subunit vaccine administered at 14 weeks of age.
A challenge dose of Rotarix will be administered at 18 weeks of age and stool samples collected just before challenge and 5, 7 & 9 days later.
|
Trivalent P2-VP8 subunit vaccine manufactured by SK Chemicals containing 90ug of each VP8 antigen derived from P[4] (DS-1), P[6] (1076), and P[8] (Wa) rotavirus strains fused to the P2 epitope from tetanus toxoid and adsorbed to aluminium hydroxide.
A single dose (0.5ml) of this vaccine is administered intramuscularly through injection.
Live-attenuated oral human rotavirus vaccine (Rotarix) manufactured by GlaxoSmithKline containing at least 10^6 CCID50(median cell culture infective doses) of G1P[8] rotavirus, RIX4414 strain produced in Vero cells.
This vaccine is an oral suspension with a single dose (1.5ml) administered using an oral applicator.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Vaccine Shedding
Time Frame: 5-9 days after Challenge
|
to detect a reduction in the proportion of children shedding vaccine rotavirus in stool at any timepoint 5 -9 days after challenge, among children immunized with P2-VP8 subunit vaccine alone or in combination with Rotarix, compared with infants receiving Rotarix alone.
We estimate that approximately 50% (range 30-70%) of children previously vaccinated with 2 doses of Rotarix will shed Rotarix detected by Polymerase Chain Reaction (PCR) at any timepoint 5-9 days after challenge
|
5-9 days after Challenge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion following vaccination
Time Frame: 14 and 18 weeks of age
|
Seroconversion After 2 doses of Rotarix in Zambia seroconversion was 60% (130/216) in an earlier study and 45% (10/22) in our Medical Research Council UK MRC-funded pilot of Rotarix challenge, based on IgA to whole virus cell culture lysate (largely anti -VP6 antibodies).
Seroconversion based on anti-VP8 antibodies has not been studied after Rotarix administration but may be similar.
|
14 and 18 weeks of age
|
Immune boosting
Time Frame: 7 days after 3rd clinic visit
|
i.) We will compare the number of gut-homing (alpha 4 beta 7+) IgA and IgG rotavirus VP8-specific ASCs 7 days after the third clinic visit in 50 infants from each study arm (i.e. after the first VP8 vaccine booster dose, after the third VP8 vaccine dose (alone or in combination with Rotarix), or after no vaccine (control) in the Rotarix only arm).
|
7 days after 3rd clinic visit
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Roma Chilengi, MD, Centre for Infectious Disease Research in Zambia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRC Rotavirus HIC
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Communicate with the participants results of the study and plans to share de-identified data. Disseminate to internal research meetings as well as the Ministry of Health Zambia.
Submit manuscripts, publications, in peer review journal and also present at local and international scientific conferences
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diarrhea
-
Aboca Spa Societa' AgricolaUnknownDiarrhea | Diarrhea, Infantile | Chronic Diarrhea | Acute Diarrhea
-
Napo Pharmaceuticals, Inc.Active, not recruitingAdult Solid Tumor | Cancer Therapy-Related Diarrhea | Chemotherapy-related Diarrhea | Prophylaxis of Diarrhea | Symptomatic Relief of Diarrhea | Targeted Therapy-related DiarrheaUnited States, Taiwan, Georgia, Serbia, Argentina
-
Hospital San BartolomeInstituto de Investigacion de las Alteraciones del Crecimiento, Desarrollo...Unknown
-
South Shore HospitalWithdrawnAntibiotic Associated Diarrhea | Clostridium Difficile Associated Diarrhea
-
Cosmo Technologies LtdBausch Health Americas, Inc.CompletedTraveler's DiarrheaGuatemala, Mexico
-
Sana'a UniversityCompleted
-
PATHUniversity of Maryland; Center for Vaccine Development - MaliCompleted
-
Johns Hopkins Bloomberg School of Public HealthNaval Medical Research CenterCompletedTravelers' DiarrheaUnited States
-
Intercell USA, Inc.CompletedTraveler's DiarrheaUnited States
-
Augusta UniversityNRS Medical College, Kolkata, West Bengal, India; School of Tropical Medicine...Terminated
Clinical Trials on Trivalent P2-VP8
-
PATHBill and Melinda Gates Foundation; Children's Hospital Medical Center, Cincinnati and other collaboratorsCompletedRotavirus VaccineSouth Africa
-
PATHThe Emmes Company, LLCCompleted
-
PATHCompletedEvaluation of a Rotavirus VaccineSouth Africa
-
PATHBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Recruiting
-
PATHCompletedRotavirus InfectionUnited States
-
Laboratorios de Biologicos y Reactivos de México...UnknownPoliomyelitisMexico
-
SeqirusNovartis VaccinesCompleted
-
Green Cross CorporationCompleted
-
Center for Disease Prevention and Control of Beijing...Completed